• Tue. May 17th, 2022

Five Corona patients were recently discharged from Hadassah Medical Center, following participation in the world’s first clinical trial of innovative treatment developed by the hospital, writes the Jerusalem Post newspaper.

Treatment with the drug Allocetra has been developed in collaboration with the Israeli pharmaceutical company Enlivex based on research conducted by Professor Dror Mevorach, Director of the Departments of Internal Medicine and Corona at Hadassah. The treatment had already been successfully given to ten patients with sepsis (blood poisoning).

All five Corona patients were hospitalized in a serious or critical condition.

– Allocetra is intended to treat a wide range of conditions where there is an overreaction from the immune system which leads to an increase in the secretion of proteins from cells in the immune system called cytokines and causes a cytokine storm. The treatment involves donating cells from a healthy donor. The cells are constructed in the laboratory in a way that, when injected into the patient’s body, will control inflammation or storm of cytokines that are otherwise very harmful to patients, explains Mevorach

The clinical test was performed with permission from Helsinki. the committee under the Ministry of Health by a team led by Prof. Vernon Van Heerden and the Director of Hadassah Medical Center’s Department of General Intensive Care.

– We are pleased that patients in serious and critical condition recovered from being treated with Allocetra. Despite the war against Corona and the intensive preparations to be able to absorb the growing number of critically ill Corona patients, Hadassah continues with innovative research and is a leader in breakthroughs in the treatment of Corona patients… [we] are happy that a drug developed on the basis of research at our hospital actually shows therapeutic potential in patients, says Professor Zeev Rotstein, Director General of Hadassah Medical Center. Read more about Hadassah here.

– I hope that the budget managers will make sure that sufficient funds come into our health system and will wake up and help us help the people, says Rotstein.


According to the Ministry of Health’s data on Thursday, the number of newly infected has again reached a new record with almost 9,000 infected in the last 24 hours. Hospitals fear rising pressure will end in a collapse of the healthcare system. At the time of writing, 248,133 Israelis have been infected since Corona broke out and 1,571 Israelis have died, according to the Times of Israel.

Of the 68,811 active Corona infected, 810 patients are hospitalized in a serious condition, of which 206 are placed on a respirator. The number is slightly lower than it was on Wednesday, when the number of seriously ill people rose for the first time to over 830. Officials have warned that hospitals would be very hard pressed when the number of serious patients would be more than 800, the newspaper writes Times of Israel.

The number of moderately and severely ill patients is expected to continue to rise rapidly over the coming days and weeks, according to a model presented by experts at the Hebrew University on Wednesday. The model predicts that the number of seriously ill will only start to fall sharply after 16 October.

While the rate of increase is expected to decrease as mortality increases, no significant deceleration is expected. Mortality in Israel is higher than the model predicted, the number of seriously ill agrees roughly with the model. Read MIFF’s article from yesterday: For the first time, Israel surpasses the United States in daily Corona deaths per capita. per capita

The percentage of moderately and severely ill patients who died increased in September, while the hospitalization period for patients who died decreased significantly. According to the report from the Hebrew University, it indicates a possible decline in the viability of the health system, either due to non-arrival at treatment or difficulties with treatment.

Leave a Reply

Your email address will not be published.